Data shows L-citrulline is 1.6 times more effective at elevating plasma L-arginine levels.
A standard way to raise the body’s blood circulation has been to increase nitric oxide production by way of L-arginine supplementation. L-arginine is a precursor to nitric oxide. Nitric oxide is a key molecular and cellular messenger that increases blood flow by dilating blood vessels. Now, researchers from ingredient supplier Kyowa Hakko Bio (New York City) say new rat studies indicate that another amino acid, L-citrulline, may actually help raise plasma L-arginine levels beyond what supplementation with just L-arginine alone can do. The company is presenting its data at next week’s International Society of Sports Nutrition Conference and Expo.
Specifically, the firm says data shows L-citrulline is 1.6 times more effective at elevating plasma L-arginine levels compared to supplementing with arginine alone.
“The importance of L-citrulline for ergogenic support is because L-citrulline is not subject to pre-systemic elimination and could be a more efficient way to elevate extracellular L-arginine levels. Preliminary research with oral L-citrulline has shown elevated plasma L-arginine concentration and augmented NO-dependent signaling,” said Dr. Darryn Willoughby, who will present the research data at the conference. Willoughby is an International Society of Sports Nutrition Fellow and associate professor of exercise and nutritional biochemistry and molecular physiology at Baylor University.
Additionally, the studies showed that L-citrulline supplementation reduced the body’s sensitivity to cold temperature by increasing blood flow to the skin.
The company says all of this new evidence may have applications not only for improving circulation and reducing sensitivity to cold, but also for heart health and sports nutrition due to nitric oxide benefits. “Compared to L-arginine, L-citrulline may be an alternative approach at NO-induced increases in muscle blood flow that may provide an anabolic approach to exercise training,” Willoughby said.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
PEA may support exercise performance in addition to its anti-inflammatory properties
June 26th 2024The branded palmitoylethanolamide (PEA) ingredient called Levagen+ significantly improved dynamic lower body power, and did not inhibit strength training adaptations unlike NSAIDs or other analgesics.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.